SOCIETAL CDMO INC (SCTL)
US75629F1093 - Common Stock
SCTL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. SCTL may be in some trouble as it scores bad on both profitability and health. SCTL is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year SCTL has reported negative net income.
In the past year SCTL has reported a negative cash flow from operations.
SCTL had negative earnings in each of the past 5 years.
In multiple years SCTL reported negative operating cash flow during the last 5 years.
1.2 Ratios
SCTL has a Return On Assets of -8.64%. This is in the better half of the industry: SCTL outperforms 74.37% of its industry peers.
The Return On Equity of SCTL (-22.61%) is better than 72.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.64% | ||
| ROE | -22.61% | ||
| ROIC | N/A |
ROA(3y)-9.46%
ROA(5y)-14.37%
ROE(3y)-27.61%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SCTL has a Gross Margin (19.17%) which is in line with its industry peers.
In the last couple of years the Gross Margin of SCTL has declined.
The Profit Margin and Operating Margin are not available for SCTL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 19.17% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1%
GM growth 5Y-15.39%
2. Health
2.1 Basic Checks
SCTL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SCTL has more shares outstanding
SCTL has more shares outstanding than it did 5 years ago.
The debt/assets ratio for SCTL has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -1.24, we must say that SCTL is in the distress zone and has some risk of bankruptcy.
SCTL has a Altman-Z score of -1.24. This is comparable to the rest of the industry: SCTL outperforms 48.74% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that SCTL is not too dependend on debt financing.
SCTL's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. SCTL outperforms 55.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.24 |
ROIC/WACCN/A
WACC11.28%
2.3 Liquidity
SCTL has a Current Ratio of 1.07. This is a normal value and indicates that SCTL is financially healthy and should not expect problems in meeting its short term obligations.
SCTL has a Current ratio of 1.07. This is amonst the worse of the industry: SCTL underperforms 85.93% of its industry peers.
A Quick Ratio of 0.86 indicates that SCTL may have some problems paying its short term obligations.
SCTL's Quick ratio of 0.86 is on the low side compared to the rest of the industry. SCTL is outperformed by 83.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.07 | ||
| Quick Ratio | 0.86 |
3. Growth
3.1 Past
SCTL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.74%, which is quite impressive.
SCTL shows a small growth in Revenue. In the last year, the Revenue has grown by 4.91%.
SCTL shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.12% yearly.
EPS 1Y (TTM)40.74%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q85.71%
Revenue 1Y (TTM)4.91%
Revenue growth 3Y12.48%
Revenue growth 5Y4.12%
Revenue growth Q2Q14.16%
3.2 Future
The Earnings Per Share is expected to grow by 31.13% on average over the next years. This is a very strong growth
Based on estimates for the next years, SCTL will show a quite strong growth in Revenue. The Revenue will grow by 9.11% on average per year.
EPS Next Y45.81%
EPS Next 2Y27.18%
EPS Next 3Y31.13%
EPS Next 5YN/A
Revenue Next Year2.59%
Revenue Next 2Y4.69%
Revenue Next 3Y6.13%
Revenue Next 5Y9.11%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
SCTL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SCTL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
SCTL's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. SCTL is cheaper than 78.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 27.26 |
4.3 Compensation for Growth
SCTL's earnings are expected to grow with 31.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.18%
EPS Next 3Y31.13%
5. Dividend
5.1 Amount
No dividends for SCTL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SOCIETAL CDMO INC
NASDAQ:SCTL (4/5/2024, 7:19:35 PM)
After market: 1.09 -0.01 (-0.91%)1.1
+0.01 (+0.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap116.26M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.64% | ||
| ROE | -22.61% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 19.17% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.07 | ||
| Quick Ratio | 0.86 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)40.74%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y45.81%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)4.91%
Revenue growth 3Y12.48%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y